Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603937 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
A Phase 3 study, sponsored by Kodiak Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT04603937 is a Phase 3 study that was terminated before completion, run by Kodiak Sciences. The registered enrollment target is 459 participants.
The verdict
NCT04603937, a Phase 3 study, was terminated before completion, sponsored by Kodiak Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
Interventions
- OTHER Sham Procedure
- DRUG Aflibercept
- DRUG KSI-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04603937
The ClinicalTrials.gov registry entry for NCT04603937 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kodiak Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham Procedure is the first listed.
NCT04603937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04603937 about?
NCT04603937 is a clinical study titled "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)". This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
What is the current status of trial NCT04603937?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2020-09-30. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04603937?
The interventions under investigation include: Sham Procedure (OTHER), Aflibercept (DRUG), KSI-301 (DRUG).
Who is sponsoring clinical trial NCT04603937?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.